Deals workspace
Medicine and biotech M&A — therapeutics, diagnostics, medtech, and clinical women's health. Descriptive analytics from public sources only.
Medicine & biotech scope — 99 companies · 51 verified deals in this workspace. Not live market data; descriptive analytics only.
Therapeutics, diagnostics, medtech, and clinical women's health — consumer brands live in a separate workspace. View Consumer health →
What Our Data Covers
Here's an honest look at our dataset — how many deals we've verified, what's disclosed, and where our analysis is strongest.
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Companies
Deals
Disclosed price
Undisclosed price
Estimand: disclosed-only observed sum (completed women's health)
disclosed among completed WH deals · adjacency excluded · coverage vs AOA Dx Follow the Exits (2000–2025) (n=). Not a market topline — see methods and docs/LIMITATIONS.md.
/99 companies ()
(51 with notes)
2012–2026
Effective n by module
Network analysis
137 nodes, 51 edges
Power: high
Competitive analysis
51 deals, 29 buyers
Power: high
Price analytics
45 disclosed prices
Power: high
Deal velocity
51 deals
Power: high
Deals by sector (target)
| Sector | Cos. | Deals | $ discl. |
|---|---|---|---|
| Breast Health | 7 | 7 | 7 |
| Contraception | 3 | 1 | 1 |
| Dermatology | 1 | 1 | 1 |
| Diagnostics | 16 | 11 | 11 |
| Fertility | 12 | 9 | 5 |
| Gynecological Surgery | 5 | 5 | 5 |
| Maternal Health | 5 | 1 | 1 |
| Menopause | 4 | 3 | 2 |
| Pelvic Health | 4 | 3 | 2 |
| Precision Medicine | 6 | 6 | 6 |
| Reproductive Health | 7 | 4 | 4 |
7 sectors with companies but no verified deals omitted.
Deals by announcement year
| Year | Deals | $ discl. |
|---|---|---|
| 2012 | 2 | 2 |
| 2016 | 4 | 4 |
| 2017 | 2 | 2 |
| 2018 | 7 | 7 |
| 2019 | 2 | 2 |
| 2020 | 7 | 7 |
| 2021 | 6 | 6 |
| 2022 | 7 | 5 |
| 2023 | 3 | 3 |
| 2024 | 9 | 7 |
| 2025 | 1 | 0 |
| 2026 | 1 | 0 |
Global source categories
- SEC EDGAR filings (acquisitions, 8-K/10-K)
- Crunchbase (funding rounds, where cited)
- Company press releases and investor relations pages
- Verified press coverage (TechCrunch, Fierce Healthcare, Business Wire, etc.)
- Company websites (descriptions, founding dates)
+30 more in dataset provenance.
Data compiled from public sources for educational visualization. Verify independently before any commercial use.
Measurement layer
Quality grades, gated-metric publication, vintage gaps, and display provenance — read from computed artifacts, not a hardcoded pipeline panel.
Company source quality
avg
Deal source quality
avg
44/98 active economic records. 31 are current-only because publicAsOfDate is missing (totalFunding 22/40, lastKnownValuation 9/58). Missing dates stay missing.
/47 computedPremium rows exactly reproducible · Deal values use announcement date only (50/50) — not a value vintage. · Pre-deal valuations with date: 49/49.
Artifact v9 · hash a6ef9998a42f · 2026-09-20T00:00:00.000Z · 66 companies and 5 deals graded D/F
Featured deal — empowerment context
HLTH/Outcomes4Me 2022 cited survey items mapped to the featured deal by analyst curation — not live outcomes or keyword affinity.
Empowerment context — Biotheranostics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Clinical trial / publication)54%cited HLTH 2022Mapping source →
- Not aware of survivorship resources (Company / product site)2 in 3cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Endomagnetics, Genomic Health, Foundation Medicine, Flatiron Health
Full cited gap matrix →Review console
Staging candidates (SEC + manual import) live in Postgres until promoted into the verified dataset. Use this console to review, attest, preview, and promote.
Queue metrics unavailable — configure Postgres to see approve/reject counts.
SEC candidate review queue
Staging rows from lacuna_deals — open a dossier to review evidence, attest promotion fields, and merge into verified JSON.
Loading queue…
Checking review session…
Who's Connected to Whom
Explore the relationships between acquirers and the women's health companies they've welcomed into their portfolios.
Deal Flow
Announced women's health M&A deals by year from verified public sources.
Comparable context & historical acquisition-pattern similarity
Deterministic context engine. Heuristic comparable context and a unitless historical acquisition-pattern similarity. Not a calibrated probability and not a five-year forecast. Outcome-only stage labels are withheld.
A Closer Look at the Network
How concentrated is the acquirer landscape? Honest statistical measures with transparent confidence intervals.
Getting to Know the Acquirers
Who's been most active, what are they building, and how do their strategies compare?
Did the Deal Deliver?
Checking in on what happened after the acquisition — did the outcomes match the promise?
Finding Companies Like Each Other
Which women's health companies share similar profiles? Explore natural groupings and see how they compare.
Exit Similarity Explorer
Deterministic context engine. Ordinal bands from disclosed factor co-occurrence. Acquired companies are a historical baseline; membership in the acquisitions array does not raise data coverage and assumption completeness.
White Space Analysis
Sectors with high company density but low M&A activity — where the next wave may form.
Time from founding to announcement
Descriptive Kaplan-Meier curves on verified founding years and announcement dates in this curated set. No hypothesis test is published.